Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study

Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study

Abstract Aims/Introduction The EMPA‐REG OUTCOME® trial demonstrated benefits of empagliflozin, a sodium‐glucose cotransporter‐2 inhibitor (SGLT2i), on cardiovascular, renal outcomes and all‐cause mortality in patients with type 2 diabetes and established cardiovascular disease. The EMPRISE study pro...

Full description

Bibliographic Details
Main Authors: Dae Jung Kim, Wayne H‐H Sheu, Wook‐Jin Chung, Daisuke Yabe, Kyoung Hwa Ha, Masaomi Nangaku, Elise Chia‐Hui Tan, Koichi Node, Atsutaka Yasui, Weiyu Lei, Sunwoo Lee, Laura Saarelainen, Anouk Deruaz‐Luyet, Moe H Kyaw, Yutaka Seino, EMPRISE East Asia Study Group
Format: Article
Language:English
Published: Wiley 2023-03-01
Series:Journal of Diabetes Investigation
Subjects:
Cardiovascular diseases
Observational study
Sodium‐glucose cotransporter 2 inhibitors
Online Access:https://doi.org/10.1111/jdi.13959

Similar Items

Similar Items